

1 Supporting Information

2 Hemocompatible nucleosome-inspired
3 heparin-mimicking hydrogel microspheres for
4 safe and efficient extracorporeal removal of
5 circulating histones in critically ill patients

6 *Yu Chen^a, Tinghang Yang^b, Shujing Wang^c, Dongmei Tong^a, Xianda Liu^a, Yupei Li^{b*},*
7 *Weifeng Zhao^{a**}, Changsheng Zhao^a*

8

9 a College of Polymer Science and Engineering, State Key Laboratory of Polymer
10 Materials Engineering, Sichuan University, Chengdu 610065, China

11 b Department of Nephrology, Kidney Research Institute, West China Hospital of
12 Sichuan University, Chengdu 610041, China

13 c Department of Nephrology, Kidney Research Institute, Frontiers Science Center for
14 Disease-related Molecular Network, West China Hospital of Sichuan University,
15 Chengdu 610041, China

16 1. EXPERIMENTAL SECTION

17 1.1. Materials

18 Polyethersulfone (PES) was purchased from BASF Chemical Company (Ultrason
19 E6020P, Germany). N-vinyl-2-pyrrolidone (VP, 99.0%), acrylic acid (AA, 99.0%), 2-
20 acrylamido-2-methyl-1-propanesulfonic acid (AMPS, 98%), N, N'-methylene
21 bis(acrylamide) (MBA, $C_7H_{10}N_2O_2$, for molecular biology, $\geq 99.0\%$), 2,2-
22 azobisisobutyronitrile (AIBN, 98.0%), ammonium persulfate (APS, $(NH_4)_2S_2O_8$, AR,
23 $\geq 98.0\%$), sodium dodecyl sulfate (SDS, 98.0%), sodium hydroxide (NaOH, 97.0%),
24 heparin sodium salt (≥ 180 USP units/mg), ethanol (CH_3CH_2OH , AR, $\geq 99.7\%$), and
25 phosphate-buffered saline (PBS, pH = 7.4) were purchased from Aladdin Reagent Co.
26 Ltd. (Shanghai, China). N, N'-Dimethylacetamide (DMAc, $\geq 99.8\%$) was purchased
27 from Chengdu Kelong Chemical Reagent Co. Ltd. (China). Bovine serum albumin
28 (BSA) and hirudin were purchased from Sigma Chemical Co. Ltd. (St. Louis, MO,
29 USA). The ungraded mixture of calf thymus histones was purchased from Sangon
30 Biotechnology Inc. (Shanghai, China). Micro BCATM protein assay reagent kit was
31 purchased from PIERCE Inc. Human complement fragment 3a (C3a) kit, and a human
32 complement fragment 5a (C5a) kit were purchased from Cusabio Biotech, China. The
33 deionized (DI) water used in all the experiments was prepared by a deionized lab water
34 system. All the chemicals were used as received.

35 1.2. Preparation of the RCHMs

36 Table S1 Composition of the reaction solution

The reaction solution	AA (g)		AMPS (g)		MBA (g)	APS (g)	DI water (g)
A ₁ M ₃	3.75	0.052	11.25	0.055	0.6	0.15	34
A ₂ M ₂	7.50	0.104	7.50	0.036	0.6	0.15	34
A ₃ M ₁	11.25	0.156	3.75	0.018	0.6	0.15	34
A ₀ M ₀	/	/	/	/	/	/	50

37 1.3. Characterization of the RCHMs

38 1.3.1. Fourier transform infrared spectroscopy (FTIR)

39 The microspheres were freeze-dried for 24 h to remove moisture, and then the dried
40 microspheres were placed in a mold and the samples were detected in the transmission
41 mode of an FTIR spectrometer (Thermo Fisher Nicolet iS50, USA) with a scan range
42 of 4000-500 cm⁻¹ and a resolution of 2 cm⁻¹. The average of 32 scans was taken as the
43 result for each sample tested.

44 1.3.2. Thermogravimetric analysis (TGA)

45 The microspheres were freeze-dried, and then the samples with a dry weight of about
46 5~10 mg was placed in a ceramic crucible. The TGA curves were obtained using a
47 thermogravimetric analyzer (METTLER TOLEDO TGA/DSC 3+, Switzerland). The
48 heating program was set to 50 °C constant temperature equilibrium for 30 min, followed

49 by heating from 50 °C to 800 °C at a heating rate of 10 °C/min, the whole test was
50 carried out under N₂ atmosphere.

51 *1.3.3. Elemental analysis (EA)*

52 The microspheres were freeze-dried, and then the samples with a dry weight of about
53 2 mg were placed into an elemental analyzer (Elementar UNICUBE, DEU) to analyze
54 the contents of carbon, nitrogen, sulfur, and hydrogen in different microspheres
55 directly. Two parallel analyses were conducted for each sample and the final elemental
56 results were averaged over the two analyses.

57 *1.3.4. X-ray photoelectron spectroscopy (XPS)*

58 The microspheres were freeze-dried and analyzed using an X-ray photoelectron
59 spectrometer (Thermo Scientific ESCALAB Xi+, USA). The vacuum degree of the
60 analysis chamber was 1×10^{-9} Pa, and the excitation source was an Al $K\alpha$ ray ($h\nu =$
61 1486.6 eV). The operating voltage was 13.4 kV, the filament current was 6 mA, and
62 the signal accumulation was performed for five cycles. The resulting data were
63 analyzed using the Thermo Scientific™ Avantage software.

64 *1.3.5. Mercury intrusion porosimetry (MIP)*

65 The microspheres were freeze-dried, and then the samples with a dry weight of
66 approximately 200 mg were subjected to analysis in an Automatic Mercury Pressure
67 Meter (MicroActive AutoPore V 9600, USA) to determine the specific surface area,
68 porosity, and pore distribution of the microspheres.

69 *1.3.6. Scanning electron microscopy (SEM)*

70 The cross-sectional samples were rapidly frozen with liquid nitrogen and then
71 sectioned with a blade. Subsequently, the samples were freeze-dried and sprayed with
72 gold on the surfaces by ion sputtering (vacuum degree 8 kPa, current 6-8 mA). This
73 was followed by observation under a scanning electron microscope (Phenom Pure,
74 Netherlands).

75 **1.4. Hemocompatibility evaluation**

76 *1.4.1. Blood collection*

77 Fresh human blood was obtained from healthy volunteers (22–28 years old) and
78 collected using 5 mL vacuum tubes (Jiangsu Kangjian Medical Products Co., Ltd.) for
79 *in vitro* hemocompatibility evaluation assays. All hemocompatibility experiments
80 complied with national guidelines (GB/T 16886.4-2003/ISO 10993-4:2002) and were
81 approved and executed by West China Hospital of Sichuan University (ethical approval
82 number: 2024553).

83 *1.4.2. Blood cell counts*

84 Blood cell count assay were performed to investigate the impact of the RCHMs on
85 blood cells. The microspheres were previously immersed in PBS overnight. 100 mg of
86 microspheres were added to 500 μ L of fresh whole blood (EDTA anticoagulated,
87 anticoagulant-to-blood ratio = 1:9 (v/v)) and incubated with the whole blood at 37 ° C
88 for 30 min. The remaining blood was then collected. The whole blood cell counts were
89 measured by an automated hematology cell analyzer (Mindray BC-5100, China)
90 according to the provided instructions. The results were expressed as the mean \pm SD (n
91 = 3).

92 *1.4.3. Hemolysis ratio*

93 The measurement of hemolysis ratio was used to evaluate the erythrocyte
94 compatibility of the microspheres. The microspheres were previously immersed in PBS
95 overnight. 5 mL of whole blood (sodium citrate anticoagulated, anticoagulant-to-blood
96 ratio = 1:9 (v/v)) was firstly added to 10 mL of calcium- and magnesium-free saline,
97 and then centrifuged at 2000 rpm for 10 min to separate the erythrocytes from the
98 plasma. This process was repeated at least five times. The erythrocytes obtained after
99 centrifugation were diluted 20 times with saline to obtain red blood cell suspension.
100 During the hemolysis test, 10 mg of microspheres were added into 1 mL of the diluted
101 red blood cell suspension and incubated at 37 °C for 3 h. The negative control was
102 prepared by combining 0.2 mL of red blood cell suspension with 0.8 mL of saline, while
103 the positive control was prepared by combining 0.2 mL of red blood cell suspension
104 with 0.8 mL of DI water. After centrifuging at 7000 rpm for 3 min, the suspensions
105 were collected to measure the absorbance of the released hemoglobin at 540 nm by a
106 UV-Vis spectrometer (UV-1750, Shimadzu Co., Ltd, Japan). The hemolysis ratios of
107 the microspheres were then calculated using Equation S1

108
$$\text{Hemolysis ratio (\%)} = \frac{A_s - A_n}{A_p - A_n} \times 100\% \quad (\text{S1})$$

109 where A_s , A_p , and A_n are the absorbance of the samples, positive control, and negative
110 control, respectively. The results were expressed as mean \pm SD (n = 3).

111 *1.4.4. Evaluation of complement activation*

112 Serum concentrations of C3a and C5a were measured by commercial ELISA kits
113 (Thermo Fisher Human Complement C3a ELISA Kit and Thermo Fisher Human

114 Complement C5a ELISA Kit) to evaluate complement activation. The microspheres
115 were previously immersed in PBS overnight. 50 mg of microspheres in each group were
116 incubated with 150 μ L of fresh blood (anticoagulated with 16000 ATU/mL
117 recombinant hirudin, anticoagulant-to-blood ratio = 1:40 (v/v)) at 37 $^{\circ}$ C for 30 min.
118 The blood co-cultured with the microspheres was centrifuged at 6500 rpm for 10 min,
119 and the supernatant was diluted (1/1000 for the C3a test, 1/25 for the C5a test). 100 μ L
120 of the diluted sample or standard solution was added to the ELISA test well plate coated
121 with the specific antibody. The detections were conducted according to the respective
122 instructions and the whole blood sample was employed as the control. The results were
123 expressed as mean \pm SD (n = 3).

124 **1.5. *In vitro* histone adsorption**

125 *1.5.1. Static histone adsorption*

126 To assess the adsorption performance of the RCHMs for histones, mixed calf thymus
127 histones were added to PBS buffer to prepare a series of histone solutions with
128 concentrations of 100, 200, and 300 μ g/mL. Then, 200 mg of the RCHMs was added
129 to 1 mL of histone solution and shaken at 37 $^{\circ}$ C for 4 h. After that, the histone
130 concentration was measured by the Micro BCATM protein assay reagent kit, and the
131 removal ratio and adsorption capacity of histones by the RCHMs were calculated
132 according to Equations S2 and S3, respectively.

$$133 \quad \text{Removal ratio (\%)} = \frac{C_0 - C_t}{C_0} \times 100\% \quad (\text{S2})$$

$$134 \quad q = \frac{(C_0 - C_t)V}{m} \times 100\% \quad (\text{S3})$$

135 where C_0 and C_t ($\mu\text{g/mL}$) are the initial and residual histone concentrations at time t , q
136 ($\mu\text{g/mg}$) is the adsorption capacity of histone, V (mL) is the histone solution volume,
137 and m (mg) is the wet weight of microspheres. The results were expressed as mean \pm
138 SD ($n = 3$).

139 The detailed information of Micro-BCATM is as follows: Micro-BCATM is a
140 detergent-compatible bicinchoninic acid formulation for the colorimetric detection and
141 quantitation of total protein. The method uses bicinchoninic acid (BCA) as the detection
142 reagent for Cu^{1+} , which is formed when Cu^{2+} is reduced by protein in an alkaline
143 environment. A purple-colored reaction product is formed by the chelation of two
144 molecules of BCA with one cuprous ion (Cu^{1+}). This water-soluble complex exhibits a
145 strong absorbance at 562 nm that is linear with increasing protein concentrations.

146 *1.5.2. Dynamic histone adsorption*

147 To investigate the adsorption kinetics of histones by microspheres, an initial
148 concentration of 300 $\mu\text{g/mL}$ was selected for the histone time-dynamic adsorption
149 assay. 200 mg of the RCHMs was incubated with 1 mL of the histone solution at 37 °C.
150 The concentrations of histones were measured at 5, 10, 15, 30, 60, 90, 120, 180, 240,
151 300, 360, and 480 min by the Micro BCATM protein assay reagent kit and the adsorption
152 capacity of histones by the RCHMs was calculated according to Equation S3. The
153 results were expressed as mean \pm SD ($n = 3$).

154 The histone adsorption kinetics results of RCHMs were then fitted with pseudo-first-
155 order (Equation S4) and pseudo-second-order (Equation S5) adsorption kinetics
156 models:

157
$$\ln(q_e - q_t) = \ln q_{e,cal,1} - k_1 t \quad (S4)$$

158
$$\frac{t}{q_t} = \frac{1}{k_2 q_{e,cal,2}^2} + \frac{t}{q_{e,cal,2}} \quad (S5)$$

159 where q_e ($\mu\text{g}/\text{mg}$) is the experimental equilibrium histone adsorption capacity; q_t
160 ($\mu\text{g}/\text{mg}$) is the histone adsorption amount at time t ; $q_{e, cal,1}$ ($\mu\text{g}/\text{mg}$) and $q_{e, cal,2}$ ($\mu\text{g}/\text{mg}$)
161 are the equilibrium histone adsorption calculated by pseudo-first-order and pseudo-
162 second-order models, respectively; and k_1 (min^{-1}) and k_2 ($\text{g min}/\text{mg}$) are the rate
163 constants of the pseudo-first-order and pseudo-second-order models, respectively. The
164 fitting parameters of the pseudo-second-order model can be used to calculate the initial
165 adsorption rate (h) using Equation S6.

166
$$h = k_2 q_{e,cal,2}^2 \quad (S6)$$

167 where h ($\text{mg g}^{-1} \text{min}^{-1}$) is the initial adsorption rate calculated by the pseudo-second-
168 order model, k_2 ($\text{g min}^{-1} \text{mg}^{-1}$) is the rate constant of the pseudo-second-order model,
169 and $q_{e, cal,2}$ ($\mu\text{g}/\text{mg}$) is the equilibrium histone adsorption amount calculated by the
170 pseudo-second-order model.

171 To investigate adsorption isotherms, histones were added to PBS to prepare histone
172 solutions with concentrations of 100, 200, 300, 600, 900, 1200, 1800, and 2400 $\mu\text{g}/\text{mL}$.
173 Then, 200 mg of the RCHMs was loaded into 1 mL of the histone solution and shaken
174 at 37 °C. By the conclusion of the previous experiment, equilibrium was reached in the
175 adsorption process at 4 h. At this point, the supernatant absorbance was measured by
176 the Micro BCA™ protein assay reagent kit at 562 nm to calculate the equilibrium
177 concentration (C_e) using a standard curve. Then, the equilibrium histone adsorption (q_e)
178 was obtained using Equation S3.

179 The isotherm results were fitted using the Langmuir and Freundlich adsorption
180 isotherm models with linear and nonlinear forms (Equations S7-10).

181 linear Langmuir model: $\frac{1}{q_e} = \frac{1}{q_m K_L C_e} + \frac{1}{q_m}$ (S7)

182 nonlinear Langmuir model: $q_e = \frac{q_m K_L C_e}{1 + K_L C_e}$ (S8)

183 linear Freundlich model: $\ln q_e = \frac{1}{n} \ln C_e + \ln K_F$ (S9)

184 nonlinear Freundlich model: $q_e = K_F C_e^{1/n}$ (S10)

185 where q_e (mg/g) is the histone adsorption amount (mg) per unit amount (g) of the
186 RCHMs at equilibrium, C_e ($\mu\text{g/mL}$) is the equilibrium histone concentrations, q_m (mg/g)
187 is the maximum adsorption capacity calculated by the Langmuir model; K_L (mL/ μg)
188 and K_F (($\mu\text{g/mg}$) (mL/ μg) $^{1/n}$) are the Langmuir and Freundlich constants, respectively;
189 $1/n$ is the constant which incorporate factors affecting the adsorbed amount at
190 equilibrium.

191 1.6. Static BSA adsorption


192 The amount of adsorbed albumin was measured by Ultraviolet spectrophotometry
193 (UV-1750, Shimadzu Co., Ltd, Japan) and Micro BCATM protein assay reagent kit. To
194 test the resistance to protein contamination of the RCHMs, BSA was added to PBS to
195 prepare BSA solutions of 300 $\mu\text{g/mL}$ and 1000 $\mu\text{g/mL}$. Then, 200 mg of the RCHMs
196 was added into the BSA solution and shaken at 37 °C for 4 h. The BSA concentration
197 was measured, and the BSA adsorption capacity was calculated according to Equations
198 S3. The results were expressed as mean \pm SD (n = 3).

199 **2. RESULTS AND DISCUSSION**

200 **2.1. Synthesis and characterizations of the microspheres**


201 **Table S2.** Analysis of elemental content in different raw materials.

Raw materials	C (wt.%)	S (wt.%)	N (wt.%)	H (wt.%)
PES	62.0	13.8	0	3.5
VP	64.8	0	12.6	8.2
AA	50.0	0	0	5.6
AMPS	40.6	15.5	6.8	6.3



203 **Figure S1.** (a) C 1s (b) N 1s and (c) S 2p fitted high-resolution XPS spectra of the
204 microspheres.

205 **2.2. Histone adsorption performance**




207 **Figure S2.** Adsorption isotherms of the RCHMs toward histones. (a) linear Langmuir
 208 and (b) linear Freundlich model fitting plots.

209 **Table S3.** Adsorption isotherm parameters of the microspheres toward histones.

Samples	nonlinear Langmuir			nonlinear Freundlich		
	q_m ($\mu\text{g}/\text{mg}$)	K_L ($\text{mL}/\mu\text{g}$)	R^2	n	K_F ($\mu\text{g}/\text{mg}$) ($\text{mL}/\mu\text{g}$) ^{1/n}	R^2
A ₀ M ₀	26.71	2.15125E-4	0.99771	1.13264	0.01055	0.99676
A ₁ M ₃	21.78	5.09257E-4	0.99036	1.26448	0.03167	0.99395
A ₂ M ₂	21.46	6.70346E-4	0.99330	1.26277	0.03801	0.98793
A ₃ M ₁	20.47	8.35232E-4	0.99551	1.28153	0.04583	0.99212

210 **2.3. Inhibition of extracellular histone-induced platelet aggregation by RCHMs**



211

212 **Figure S3.** Platelet volume distribution histogram in histone-treated whole blood

213 samples.